公开(公告)号：US20240245638A1

公开(公告)日：2024-07-25

申请号：US18683935

申请日：2022-08-19

Applicant: Clexio Biosciences Ltd.

Inventor： Dorit MIMROD ,  Elijahu BERKOVICH ,  Dvora IZGELOV

IPC: A61K31/198 ,  A61K9/48

CPC classification number: A61K31/198 ,  A61K9/4825

Abstract: The disclosure is directed to methods of treating Parkinson's disease comprising administration of a capsule comprising an anti-parkinsonian medication and where the capsule's length is at least about 29 mm and the capsule's width at least about 9.5 mm.

公开(公告)号：US12016832B2

公开(公告)日：2024-06-25

申请号：US17571731

申请日：2022-01-10

Applicant: Clexio Biosciences Ltd.

Inventor： Elena Kagan ,  Gina Pastino

IPC: A61K31/135 ,  A61K9/00 ,  A61K9/16 ,  A61K31/136 ,  A61K31/15 ,  A61K31/343 ,  A61K31/36 ,  A61K31/381 ,  A61K31/7034 ,  A61P25/24

CPC classification number: A61K31/135 ,  A61K9/0053 ,  A61K9/1611 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/167 ,  A61K31/136 ,  A61K31/15 ,  A61K31/343 ,  A61K31/36 ,  A61K31/381 ,  A61K31/7034 ,  A61P25/24

Abstract: The present invention provides a method for safe and efficacious administration of esketamine.

公开(公告)号：US20240074991A1

公开(公告)日：2024-03-07

申请号：US18504388

申请日：2023-11-08

Applicant: Clexio Biosciences Ltd.

Inventor： Elena KAGAN ,  Gina PASTINO

IPC: A61K31/135 ,  A61K9/00 ,  A61K9/16 ,  A61K31/136 ,  A61K31/15 ,  A61K31/343 ,  A61K31/36 ,  A61K31/381 ,  A61K31/7034 ,  A61P25/24

CPC classification number: A61K31/135 ,  A61K9/0053 ,  A61K9/1611 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/167 ,  A61K31/136 ,  A61K31/15 ,  A61K31/343 ,  A61K31/36 ,  A61K31/381 ,  A61K31/7034 ,  A61P25/24

Abstract: The present invention provides a method for safe and efficacious administration of esketamine.

公开(公告)号：US11865088B2

公开(公告)日：2024-01-09

申请号：US16592930

申请日：2019-10-04

Applicant: Clexio Biosciences Ltd.

Inventor： Elena Kagan ,  Gina Pastino

IPC: A61K31/135 ,  A61P25/24 ,  A61K31/136 ,  A61K31/15 ,  A61K31/343 ,  A61K31/36 ,  A61K31/381 ,  A61K31/7034 ,  A61K9/00 ,  A61K9/16

CPC classification number: A61K31/135 ,  A61K9/0053 ,  A61K9/167 ,  A61K9/1611 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1652 ,  A61K31/136 ,  A61K31/15 ,  A61K31/343 ,  A61K31/36 ,  A61K31/381 ,  A61K31/7034 ,  A61P25/24

Abstract: The present invention provides a method for safe and efficacious administration of esketamine.

公开(公告)号：US11844796B2

公开(公告)日：2023-12-19

申请号：US17527528

申请日：2021-11-16

Applicant: Clexio Biosciences Ltd.

Inventor： Dinesh K. Haswani ,  Derek V. Moe ,  Victoria A. O'Neill ,  Manuel A. Vega Zepeda

IPC: A61K31/485 ,  A61K9/16 ,  A61K31/167 ,  A61K31/165 ,  A61K31/515 ,  A61K31/5513 ,  A61K31/135 ,  A61K31/437 ,  A61K31/554 ,  A61K31/137 ,  A61K31/4458 ,  A61K9/20 ,  A61K31/192 ,  A61K31/4402 ,  A61K31/616 ,  A61K9/00 ,  A61K9/50 ,  A61K31/16

CPC classification number: A61K31/485 ,  A61K9/0053 ,  A61K9/1676 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2063 ,  A61K9/2081 ,  A61K9/5015 ,  A61K9/5031 ,  A61K9/5047 ,  A61K31/135 ,  A61K31/137 ,  A61K31/16 ,  A61K31/165 ,  A61K31/167 ,  A61K31/192 ,  A61K31/437 ,  A61K31/4402 ,  A61K31/4458 ,  A61K31/515 ,  A61K31/554 ,  A61K31/5513 ,  A61K31/616 ,  A61K9/5026 ,  A61K9/5078 ,  A61K31/192 ,  A61K2300/00 ,  A61K31/167 ,  A61K2300/00 ,  A61K31/485 ,  A61K2300/00

Abstract: Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.

公开(公告)号：US20230398098A1

公开(公告)日：2023-12-14

申请号：US18455242

申请日：2023-08-24

Applicant: Clexio Biosciences Ltd.

Inventor： Mark ZAMANSKY ,  Anton FRENKEL

IPC: A61K31/4164 ,  A61K9/08 ,  A61K47/10 ,  A61K9/00

CPC classification number: A61K31/4164 ,  A61K9/08 ,  A61K47/10 ,  A61K9/0014

Abstract: The present disclosure relates to a purified detomidine HCl pharmaceutical product and to methods of preparation, validation of pharmaceutically acceptable product and use thereof.

公开(公告)号：US20230301941A1

公开(公告)日：2023-09-28

申请号：US18184270

申请日：2023-03-15

Applicant: Clexio Biosciences Ltd.

Inventor： Derek MOE ,  Randal SEBURG ,  Sagar RANE

IPC: A61K31/135 ,  A61K9/20

CPC classification number: A61K31/135 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054

Abstract: Disclosed herein are immediate release oral dosage forms that contain abuse-deterrent and abuse-resistant features. In particular, the disclosed dosage forms can provide deterrence of abuse by ingestion of multiple individual doses. The disclosed dosage forms can likewise provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses. The dosage forms may also exhibit abuse resistant properties when physically manipulated, and also when physically manipulated and then administered in a manner not consistent with oral dosing. The dosage forms may also exhibit abuse resistant properties when administered in a manner intended to result in administration of the esketamine in a higher than therapeutic dose.

公开(公告)号：US20230255884A1

公开(公告)日：2023-08-17

申请号：US17607688

申请日：2020-05-01

Applicant: CLEXIO BIOSCIENCES LTD.

Inventor： Erez KOREN ,  Richard FISHER

IPC: A61K9/00 ,  A61K31/167 ,  A61K47/26 ,  A61K31/196 ,  A61K31/4174 ,  A61K31/192 ,  A61K47/10

CPC classification number: A61K9/0092 ,  A61K31/167 ,  A61K47/26 ,  A61K31/196 ,  A61K31/4174 ,  A61K31/192 ,  A61K47/10

Abstract: The invention is directed to fibrous structures finished with active pharmaceutical ingredients, as well as methods of their manufacturer and use.

公开(公告)号：US20220211617A1

公开(公告)日：2022-07-07

申请号：US17514851

申请日：2021-10-29

Applicant: Clexio Biosciences Ltd.

Inventor： Avshalom Ben Menachem ,  Ilan Zalit

IPC: A61K9/00 ,  A61K9/20 ,  A61M31/00

Abstract: An oral gastro-retentive delivery device is provided which unfolds rapidly upon contact with gastric juice. The device is configured in a collapsed configuration for oral intake and unfolding for gastric retention for a predetermined period of time and eventually reducing in size for passage through the rest of the GI track.

公开(公告)号：US11324707B2

公开(公告)日：2022-05-10

申请号：US16869309

申请日：2020-05-07

Applicant: Clexio Biosciences Ltd.

Inventor： Derek Moe ,  Randal Seburg ,  Sagar Rane

IPC: A61K31/135 ,  A61K9/16 ,  A61K9/00 ,  A61K31/78 ,  A61K33/10

Abstract: Disclosed herein are immediate release oral dosage forms that contain abuse-deterrent and abuse-resistant features. In particular, the disclosed dosage forms can provide deterrence of abuse by ingestion of multiple individual doses. The disclosed dosage forms can likewise provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses. The dosage forms may also exhibit abuse resistant properties when physically manipulated, and also when physically manipulated and then administered in a manner not consistent with oral dosing. The dosage forms may also exhibit abuse resistant properties when administered in a manner intended to result in administration of the esketamine in a higher than therapeutic dose.